cas 59074-26-9|| where to buy 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

製品名:3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

IUPAC Name:3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

包装単位	有効在庫	価格（USD）
CM126738-1g	in stock	ƿƿ
CM126738-5g	in stock	ȯƃǑ
CM126738-25g	1-2 Weeks	ƛŞȡ
CM126738-100g	1-2 Weeks	ȯǫƿƃ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 59074-26-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:59074-26-9; 分子式:C15H13ClN2; 融点:-; SMILESコード:ClC1=CC=C(C2=NNCC2C3=CC=CC=C3)C=C1; 密度:

: カタログ番号:CM126738; 分子量:256.73; 沸点:393°C at 760 mmHg; MDL番号:MFCD07776855; 保管方法:Store at 2-8°C.

: Pyrazolines; Pyrazoline is a heterocyclic chemical compound with the molecular formula C3H6N2. Pyrazolines are well-known and important nitrogen-containing five-membered ring heterocyclic compounds. Pyrazoline derivatives have numerous prominent pharmacological effects, such as antimicrobial, anti-inflammatory, analgesic, antidepressant and anticancer.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.

: Monlunabant; Obesity is linked to overactivity of the endocannabinoid system that regulates appetite, fat storage, and insulin resistance. Cannabinoid receptor type-1 (CB1) belongs to the G protein-coupled receptor (GPCR) superfamily, and are found in the brain and peripheral tissues. Pharmacological blockers of CB1 receptors have demonstrated effectiveness in suppressing appetite, inducing weight loss, enhancing energy expenditure and speeding up metabolism.
Novo Nordisk’s Monlunabant is a novel peripherally-acting CB1 receptor blocker. This target limits brain penetration and minimizes psychiatric side-effects. Monlunabant is developed for the treatment of metabolic disorders. The phase 2 trials for diabetic kidney disease and obesity is expected in the second half of 2024.